Lyell Immunopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $850.0K | $130.3M |
| FY2019 | — | $-111.1M | $96.7M |
| FY2020 | — | $-292.5M | $140.4M |
| FY2021 | — | $929.8M | $293.8M |
| FY2022 | — | $833.3M | $123.6M |
| FY2023 | — | $655.0M | $145.6M |
| FY2024 | — | $382.8M | $105.6M |
| FY2025 | — | $248.2M | $60.2M |